New emerging targets in cancer immunotherapy: the role of TIM3

Currently, the programmed death-1/programmed death ligand-1 and the cytotoxic T-lymphocyte-associated protein 4 are the two commonly targeted immune-checkpoint inhibition pathways. These drugs have significantly improved the prognosis of many cancer types. While immune-checkpoint inhibitors have rev...

Descripción completa

Detalles Bibliográficos
Autores principales: Friedlaender, Alex, Addeo, Alfredo, Banna, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6579568/
https://www.ncbi.nlm.nih.gov/pubmed/31275616
http://dx.doi.org/10.1136/esmoopen-2019-000497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6579568/
https://www.ncbi.nlm.nih.gov/pubmed/31275616
http://dx.doi.org/10.1136/esmoopen-2019-000497

Ejemplares similares